AiCure

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


INC Research launches its IPO

Monday, November 10, 2014 02:38 PM

Global CRO INC Research launched its initial public offering today, raising $150 million by selling just over 8.1 million shares at $18.50 per share—the middle of the expected $17-$20 range. The stock climbed 9% in early trading past $20.75 before settling to $20 by late afternoon.

More... »


UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »


Medidata, PPD partner to offer new approach to risk-based monitoring

Monday, November 10, 2014 12:22 PM

Medidata, a New York-based global provider of cloud-based solutions for clinical research in life sciences, and Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based global CRO, are expanding their partnership to provide the life science industry with a more comprehensive approach to risk-based monitoring (RBM)—aimed at conducting drug development more intelligently, more quickly and more cost-effectively.

More... »

Idera Pharmaceuticals, Parent Project Muscular Dystrophy collaborate

Monday, November 10, 2014 12:20 PM

Idera Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company, and nonprofit organization Parent Project Muscular Dystrophy (PPMD), based in Hackensack, N.J., are collaborating to advance Idera's proprietary Toll-like receptor (TLR) technology for the treatment of Duchenne muscular dystrophy.

More... »

Felicitex Therapeutics, Selvita collaborate to target cancer quiescence

Monday, November 10, 2014 12:18 PM

Cambridge, Mass.-based Felicitex Therapeutics, a privately owned drug discovery company, and Selvita, a Polish biotechnology company, have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors.

More... »

Charles River, CHDI Foundation extend Huntington's disease collaboration

Monday, November 10, 2014 12:18 PM

CRO Charles River International, based in Wilmington, Mass., and the CHDI Foundation, a U.S., privately-funded, nonprofit, biomedical research organization, have extended an ongoing collaboration for an additional five years through 2019. The collaboration, which began in 2005, is focused on discovering novel drugs for Huntington's disease.

More... »

Datatrak expands offices into Chicago

Monday, November 10, 2014 12:16 PM

Datatrak International, a developer of cloud-based, unified eClinical technologies for the clinical trials industry, will expand office locations to include downtown Chicago in early 2015.

More... »

Study: CNS drugs have lower regulatory success rate, take longer to develop

Monday, November 10, 2014 12:02 PM

Developing drugs to treat a wide array of central nervous systems disorders—including depression, psychosis, epilepsy and Alzheimer’s disease—takes longer and has an overall success rate of less than half that of other types of drug candidates.

More... »

The quest to transition from Sub Investigator to Principal Investigator

Monday, November 10, 2014 07:00 AM

Dr. Smith certainly is the most earnest and resourceful investigator I have encountered in my clinical research career.

More... »

Stephen T. Sonis joins PlasmaTech Biopharmaceuticals' scientific advisory board

Friday, November 7, 2014 02:07 PM

PlasmaTech Biopharmaceuticals, a biopharmaceutical company advancing patient care in critical areas, has announced that Stephen T. Sonis, DMD, DMSc, has joined its scientific advisory board (SAB). A world-renowned expert in the clinical treatment and research of cancer-related mucosal toxicities, Sonis has collaborated with management in recent years on advancing the company's clinical efforts of its oral mucositis treatment, MuGard.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs